RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS
Acta Neuropathologica · 2024-06 · 147 (1)
DOI: 10.1007/s00401-024-02705-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Neuropathologica, online erschienen am 05.03.2024. Verfasst von Holly Spence und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Aptamers, Nucleotide. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NINDS NIH HHS, NIH HHS.
Abstract (Originalsprache)
TDP-43 is an aggregation-prone protein which accumulates in the hallmark pathological inclusions of amyotrophic lateral sclerosis (ALS). However, the analysis of deeply phenotyped human post-mortem samples has shown that TDP-43 aggregation, revealed by standard antibody methods, correlates poorly with symptom manifestation. Recent identification of cryptic-splicing events, such as the detection of Stathmin-2 ( STMN-2 ) cryptic exons, are providing evidence implicating TDP-43 loss-of-function as a potential driving pathomechanism but the temporal nature of TDP-43 loss and its relation to the disease process and clinical phenotype is not known. To address these outstanding questions, we used a novel RNA aptamer, TDP-43 APT , to detect TDP-43 pathology and used single molecule in situ hybridization to sensitively reveal TDP-43 loss-of-function and applied these in a deeply phenotyped human post-mortem tissue cohort. We demonstrate that TDP-43 APT identifies pathological TDP-43, detecting aggregation events that cannot be detected by classical antibody stains. We show that nuclear TDP-43 pathology is an early event, occurring prior to cytoplasmic accumulation and is associated with loss-of-function measured by coincident STMN-2 cryptic splicing pathology. Crucially, we show that these pathological features of TDP-43 loss-of-function precede the clinical inflection point and are not required for region specific clinical manifestation. Furthermore, we demonstrate that gain-of-function in the form of extensive cytoplasmic accumulation, but not loss-of-function, is the primary molecular correlate of clinical manifestation. Taken together, our findings demonstrate implications for early diagnostics as the presence of STMN-2 cryptic exons and early TDP-43 aggregation events could be detected prior to symptom onset, holding promise for early intervention in ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
- EaStCHEM School of Chemistry, University of Edinburgh, Edinburgh, UK.
- IRR Chemistry Hub, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
- Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
- Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.
- RNA System Biology Lab, Instituto Italiano di Tecnologia, Genoa, Italy.
ORCID-Profile: Jenna M Gregory
Förderung
- Medical Research Council
- NINDS NIH HHS
- NIH HHS
- Target ALS
- NIH
- HORIZON EUROPE European Research Council
Zitieren
APA
Spence, H., Waldron, F. M., Saleeb, R. S., Brown, A. L., Rifai, O. M., Gilodi, M., Read, F., Roberts, K., Milne, G., Wilkinson, D., O'Shaughnessy, J., Pastore, A., Fratta, P., Shneider, N., Tartaglia, G. G., Zacco, E., Horrocks, M. H., & Gregory, J. M. (2024). RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta Neuropathologica, 147(1). https://doi.org/10.1007/s00401-024-02705-1
Vancouver
Spence H, Waldron FM, Saleeb RS, Brown AL, Rifai OM, Gilodi M, et al. RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS. Acta Neuropathologica. 2024;147(1). doi:10.1007/s00401-024-02705-1
BibTeX
@article{Spence2024,
author = {Spence, Holly and Waldron, Fergal M and Saleeb, Rebecca S and Brown, Anna-Leigh and Rifai, Olivia M and Gilodi, Martina and Read, Fiona and Roberts, Kristine and Milne, Gillian and Wilkinson, Debbie and O'Shaughnessy, Judi and Pastore, Annalisa and Fratta, Pietro and Shneider, Neil and Tartaglia, Gian Gaetano and Zacco, Elsa and Horrocks, Mathew H and Gregory, Jenna M},
title = {RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS},
journal = {Acta Neuropathologica},
year = {2024},
volume = {147},
number = {1},
doi = {10.1007/s00401-024-02705-1}
}
EUVIMED